Adaptive Biotechnologies Corp vs Dover Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Dover Corp trades at $209 (market cap $28.07B). The key difference: Dover Corp is far larger — about 6.9× Adaptive Biotechnologies Corp's market cap, and Dover Corp pays a 1.01% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DOV | |
|---|---|---|
Market Cap | $4.04B | $28.07B |
Sector | Health | Industrials |
52-Week High | $25.45 | $233.31 |
52-Week Low | $12.30 | $161.16 |
Enterprise Value | $4.10B | $29.58B |
Dividend Yield | — | 1.01% |
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →